cimb-logo

Journal Browser

Journal Browser

Advances in Molecular Therapies and Disease Associations in Diabetes

A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 214

Special Issue Editors


E-Mail Website
Guest Editor
School of Systems Biology, George Mason University, Fairfax, VA 22030, USA
Interests: bioinformatics; genetic network analysis; biomarker discovery; data integration; machine learning in biomedical research; systems biology; drug development; medical image analysis; neurodegenerative diseases; statistical modeling

E-Mail Website
Guest Editor
Department of Biology, Howard University, Washington, DC 20059, USA
Interests: bioinformatics; mental disorders; next-generation sequencing; machine learning; protein structure modeling
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Diabetes mellitus is a multifaceted metabolic disorder characterized by chronic hyperglycemia due to defects in insulin secretion, action, or both. Beyond its primary impact on glucose metabolism, diabetes significantly influences various physiological systems, increasing the risk of comorbid conditions such as cardiovascular diseases, neurodegenerative disorders, certain cancers, and autoimmune diseases. Understanding these molecular interconnections is crucial for developing targeted therapeutic strategies.

This Special Issue seeks to highlight recent advancements in molecular therapies for diabetes management and elucidate the complex interplay between diabetes and related diseases at the molecular level. We welcome original research articles and comprehensive reviews that delve into the following topics:

  • Molecular Mechanisms: Studies exploring pathways linking diabetes to other diseases, including inflammatory processes, endoplasmic reticulum stress, and mitochondrial dysfunction;
  • Therapeutic Targets: Identification and validation of novel molecular targets for therapeutic intervention, such as glucose-sensitive insulin analogs which adjust activity based on blood glucose levels, thereby reducing hypoglycemia risk;
  • Drug Development: Innovative therapeutic approaches, including the design of multi-receptor agonists which simultaneously activate multiple peptide hormone receptors to enhance efficacy in treating obesity and type 2 diabetes;
  • Multi-Omics Approaches: Integration of genomics, proteomics, metabolomics, and system biology to uncover biomarkers and pathways pertinent to diabetes and its comorbidities.

Dr. Hongbao Cao
Dr. Shaolei Teng
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetes
  • molecular therapies
  • comorbidities
  • genomics
  • proteomics
  • metabolomics
  • multi-omics
  • precision medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

34 pages, 1051 KiB  
Review
Atrial Fibrillation in Diabetes: Pathogenesis and Targeted Rhythm Control Strategies
by Konstantinos Grigoriou, Paschalis Karakasis, Konstantinos Pamporis, Panagiotis Theofilis, Dimitrios Patoulias, Efstratios Karagiannidis, Barbara Fyntanidou, Antonios P. Antoniadis and Nikolaos Fragakis
Curr. Issues Mol. Biol. 2025, 47(7), 559; https://doi.org/10.3390/cimb47070559 - 17 Jul 2025
Abstract
Diabetes mellitus and atrial fibrillation (AF) frequently coexist, creating a complex bidirectional relationship that exacerbates cardiovascular risk and challenges clinical management. Diabetes fosters a profibrotic, pro-inflammatory, and proarrhythmic atrial substrate through a constellation of pathophysiologic mechanisms, including metabolic remodeling, oxidative stress, mitochondrial dysfunction, [...] Read more.
Diabetes mellitus and atrial fibrillation (AF) frequently coexist, creating a complex bidirectional relationship that exacerbates cardiovascular risk and challenges clinical management. Diabetes fosters a profibrotic, pro-inflammatory, and proarrhythmic atrial substrate through a constellation of pathophysiologic mechanisms, including metabolic remodeling, oxidative stress, mitochondrial dysfunction, ion channel dysregulation, and autonomic imbalance, thereby promoting AF initiation and progression. Conventional rhythm control strategies remain less effective in diabetic individuals, underscoring the need for innovative, substrate-targeted interventions. In this context, sodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as promising agents with pleiotropic antiarrhythmic properties, modulating fibrosis, inflammation, and mitochondrial integrity. Moreover, advances in anti-inflammatory, antifibrotic, and ion channel-modulating therapeutics, coupled with novel mitochondrial-targeted strategies, are reshaping the therapeutic landscape. Multi-omics approaches are further refining our understanding of diabetes-associated AF, facilitating precision medicine and biomarker-guided interventions. This review delineates the molecular nexus linking diabetes and AF, critically appraises emerging rhythm control strategies, and outlines translational avenues poised to advance individualized management in this high-risk population. Full article
(This article belongs to the Special Issue Advances in Molecular Therapies and Disease Associations in Diabetes)
Show Figures

Figure 1

Back to TopTop